Successful Treatment of SAM Syndrome With Secukinumab Monotherapy: A Case Report of a 16-Month-Old Infant

Qiaoyu Cao; Jia Hou; Chaolan Pan; Li Zhang; Daian Cheng; Xiaochuan Wang; Ming Li

doi:10.1089/derm.2023.0222

Successful Treatment of SAM Syndrome With Secukinumab Monotherapy: A Case Report of a 16-Month-Old Infant

Dermatitis. 2023 Sep 28. doi: 10.1089/derm.2023.0222. Online ahead of print.

Authors

Qiaoyu Cao¹, Jia Hou², Chaolan Pan¹, Li Zhang^{2

3}, Daian Cheng⁴, Xiaochuan Wang², Ming Li¹

Affiliations

¹ From the Department of Dermatology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
² Department of Clinical Immunology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
³ Department of Respiratory, Hangzhou Children's Hospital, Zhejiang, China; and.
⁴ Dermatology Center, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

PMID: 37768788
DOI: 10.1089/derm.2023.0222

Abstract

Severe dermatitis, multiple allergies, and metabolic wasting (SAM) syndrome is a rare congenital skin disease. We report on a 16-month-old infant presenting with severe disseminated dermatitis, characterized by erythema and lichenified plaques. The crucial result of de novo missense mutation in the DSP gene (c.1769T>C, p.F590S) discovered by next-generation sequencing finally confirmed the diagnosis of SAM syndrome. The eruptions and skin pruritus significantly improved after a 4-week treatment with secukinumab.